Литература. 
Применение тадалафила у больных с эректильной дисфункцией

1. Ayta IA, mckinlay JB, krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. (1999) 84(l):50−56.

2. Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS: On life satisfaction in male erectile dysfunction. Int. J. Impotence Res. (1997) 9:141−148.

3. Stolk EA, Busschbach JJV: Are patients and the general public likeminded about the effect of erectile dysfunction on quality of life? Urology (2003) 61:810−815.

4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Ageing Study. J. Urol. (1994) 151:54−61.

5. Dean J, Hackett GI, Gentile V, et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006; 3: 650−61.

6. Marumo K, Murai M: Ageing and erectile dysfunction: the role of ageing and concomitant chronic illness. Int. J. Urol. (2001) 8(8):S50-S57.

7. Meuleman EJ, Donkers LH, Robertson C, Keech M, Boyle P, Kiemeney LA: ED: prevalence and effect on the quality of life; Boxmeer study. Ned. Tijdschr. Geneeskd. (2001) 145(12):576−581.

8. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M Engelmann U: Epidemiology of ED: results of the `Cologne Male Survey'. Int. J. Impot. Res. (2000) 12:305−311.

9. Mulligan T, Retchin SM, Chinchilli VM, Betinger CB: The role of ageing and chronic disease in sexual dysfunction. J. Am. Geriatr. Soc. (1988) 36:520−524.10. Meuleman EJ: Prevalence of erectile dysfunction: need for treatment? Int. J. Impot. Res. (2002) 14(Suppl. 1):S22-S28.

11. Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276−81.

12. Hellstrom WJ et al. Tadalafil has no clinical relevant effects on semen characteristics. J Urol 2003; 169(4 SUPPL):245.

13. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res 2002; 7: 435−46.

14. Seftel AD: ED in the elderly: epidemiology, aetiology and approaches to treatment. J. Urol. (2003) 169:1999;2007.

15. Saenz DE, Tejada I, Anglin G, Knight JR, Emmick JT: Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care (2002) 25(12):2159−2164.

16. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332−6.

17. Montorsi F, Nathan HP, McCullough A, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004; 172: 1036−41.

18. Qaseem A, Snow V, Denberg TD, et al. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the american college of physicians. Ann Intern Med 2009; 151: 639−49.

19. von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499−507; discussion -9.

20. Hatzichristou D, Haro JM, Martin-Morales A, et al. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. Int J Clin Pract 2007; 61: 1850−62.

21. Vardenafil SmPC 2003.

22. Tadalafil SmPC 2002.